This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Nathan Sadeghi-Nejad


Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza┬┐s Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.

Nathan Sadeghi-Nejad
By This Author:
Page 3 of 5

Rethinking Idenix Pharma in Wake of Bristol's Hep C Blow Up

By Nathan Sadeghi-Nejad

The two Hep C drugs are similar enough chemically to warrant caution.

07:00AM 08/06/12

Gilead Sciences Firing On All Cylinders

By Nathan Sadeghi-Nejad

Gilead posted strong second-quarter earnings and is moving ahead aggressively with its new hepatitis C drugs.

07:00AM 07/30/12

The Health Care Short Sales That Never Fit

By Nathan Sadeghi-Nejad

Valuation shorts can be investment quicksand, explains TheStreet columnist Nate Sadeghi.

07:00AM 07/23/12

Eli Lilly, Verastem and the Defenders of Shareholder Value

By Nathan Sadeghi-Nejad

TheStreet contributor Nate Sadeghi calls for healthcare investors to start acting like owners.

07:07AM 07/16/12

Onyx Pharma Must Start Delivering Profits

By Nathan Sadeghi-Nejad

With a second cancer drug approval looming, Onyx can join a select group of successful and profitable biotech companies.

08:10AM 07/10/12

ObamaCare Upheld: Health Care Stock Winners and Losers

By Nathan Sadeghi-Nejad

TheStreet's Nathan Sadeghi-Nejad examines which health care stocks benefit from the Supreme Court's decision to uphold health care reform.

11:38AM 06/28/12

Arena Pharma And The Fat Lady's Song

By Nathan Sadeghi-Nejad

Advice to lorcaserin bulls: Cherish the moment but sell Arena, says TheStreet contributor Nate Sadeghi.

11:13AM 06/25/12

Alkermes Needs to Build on Drug Delivery Success

By Nathan Sadeghi-Nejad

An undervalued stock could move higher if Alkermes continues to grow through acquisitions.

07:00AM 06/18/12

A Reckoning Approaches: Supreme Court and Obama's Healthcare Reform Law

By Nathan Sadeghi-Nejad

Six possible outcomes of the Court's healthcare ruling and what it means for healthcare stocks.

07:09AM 06/11/12

Bad Romance: Glaxo's Brutal Courtship of Human Genome Sciences

By Nathan Sadeghi-Nejad

Contributor Nathan Sadeghi-Nejad offers tips to Glaxo's CEO on how to woo the stubborn HGSI into marriage.

07:45AM 06/04/12

Page 3 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 17,387.21 -291.49 -1.65%
S&P 500 2,029.55 -27.54 -1.34%
NASDAQ 4,681.4970 -90.2660 -1.89%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs